Три инфекции - одна защита


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

В настоящее время актуальными остаются инфекционные заболевания, вакцинация от которых давно проводится во всем мире. За последний год в период пандемии новой коронавирусной инфекции, по данным Роспотребнадзора, отмечается снижение заболеваемости инфекционными болезнями в Российской Федерации. Большую роль в этом сыграли ограничительные меры, вводимые с целью уменьшения количества личных контактов между людьми. Однако случаи заболевания корью и паротитом все так же регистрируются на территории нашей страны, несмотря на уменьшение явлений миграции и эмиграции. Это позволяет сделать вывод о недостаточном охвате вакцинацией населения против этих инфекций, недоучете непривитых лиц или недостаточном уровне выработки защитных антител, которые позволили бы избежать заболевания.

Полный текст

Доступ закрыт

Об авторах

К. К Тихомирова

Детский научно-клинический центр инфекционных болезней ФМБА;Санкт-Петербургский государственный педиатрический медицинский университет

Email: tihksen@mail.ru
младший науч. сотр. научно-исследовательского отдела вакцинопрофилактики и поствакцинальной патологии 197022, Россия, Санкт-Петербург, ул. Профессора Попова, 9

С. М Харит

Детский научно-клинический центр инфекционных болезней ФМБА;Санкт-Петербургский государственный педиатрический медицинский университет

Санкт-Петербург, Россия

Список литературы

  1. О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2020 году. Государственный доклад. М, 2021. 256 с. @@On the state of sanitary and epidemiological well-being of the population in the Russian Federation in 2020. State report. M 2021. 256p. (in Russ.).
  2. Patel M.K., Goodson J.L., Alexander J.P, et al. Progress Toward Regional Measles Elimination -Worldwide, 2000-2019. MMWR Morb Mortal Wkly Rep. 2020;69(45):1700-1705. doi: 10.15585/mmwr.mm6945a6.
  3. Fielding J., Friedman E.A., Xu J. Safe Vaccinations for a Healthy Nation increasing US Vaccine Coverage Through Law, Science, and Communication, American Medical Association. JAMA. 2019 april 19. doi: 10.1001/jama.2019.4270.
  4. Roberts L. Why measles deaths are surging -and coronavirus could make it worse Nature. 2020;580(7804):446-47. Doi: 10.1038/ d41586-020-01011-6.
  5. McLean H.Q, Fiebelkorn A.P, Temte J.L., Wallace G.S. Centers for Disease Control and Prevention. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2013;62(RR-04):1-34.
  6. Jin, L, Orvell C, Myers R., et al. Genomic diversityof mumps virus and global distribution of the 12 genotypes. Rev Med Virol. 2015;25:85-101. doi: 10.1002/rmv.1819.
  7. Rubin S.A, Qi L, Audet S.A., et al. Antibody induced by immunization with the jeryl lynn mumps vaccine strain effectively neutralizes a heterologous wild-type mumps virus associated with a large outbreak. J Infect Dis. 2008;198:508-15. doi: 10.1086/590115.
  8. National Center for Biotechnology Information (NCBI) Taxonomy browser. [(accessed on 7 April 2018)]; Available on-line: https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=1979165.
  9. Galazka A.M., Robertson S.E., Kraigher A. Mumps and mumps vaccine: A global review. Bull WHO. 1999;77:3-14.
  10. Cheng W.Y, Liu M.T. Molecular characteristics of mumps viruses isolated in Taiwan from 2006 to 2016. Heliyon. 2018;4:e00518. Doi: 10.1016/j. heliyon.2018.e00518.
  11. Drexler J.F, Corman V.M., Muller M.A., et al. Ba ts host major mammalian paramyxoviruses. Nat Commun. 2012;3:796. doi: 10.1038/ncomms1796.
  12. Katoh H, Kubota T., Ihara T., et al. Cross-neutralization between human and African bat mumps viruses. Emerg Infect Dis. 2016;22:703-6. Doi: 10.3201/ eid2204.151116.
  13. Henle G., Henle W., Wendell K.K., Rosenberg P Isolation of mumps virus from human beings with induced apparent or inapparent infections. J Exp Med. 1948;88:223-32. Doi: 10.1084/ jem.88.2.223.
  14. Dittrich S., Hahne S., van Lier A., et al. Assessment of serological evidence for mumps virus infection in vaccinated children. Vaccine. 2011;29(49):9271-75. doi: 10.1016/j.vaccine.2011.09.072.
  15. Centers for Disease Control and Prevention (CDC) Updated recommendations for isolation of persons with mumps. MMWR Morb Mortal Wkly Rep. 2008;57:1103-105.
  16. Philip R.N., Reinhard K.R., Lackman D.B. Observations on a mumps epidemic in a virgin population. Am J Hyg. 1959;69:91-111. doi: 10.1093/oxfordjournals.aje.a119992.
  17. Dayan G.H., Quinlisk M.P, Parker A.A., et al. Recent resurgence of mumps in the United States. N Engl J Med. 2008;358:1580-89. Doi: 10.1056/ NEJMoa0706589.
  18. O'Brien P.K., Smith D.S., Galpin O.P Acute pancreatitis and haemolytic anaemia associated with mumpsvirus infection. Br Med J. 1965;ii:1529. doi: 10.1136/bmj.2.5477.1529.
  19. Anderson R.M., Crombie J.A., Grenfell B.T. The epidemiology of mumps in the UK: A preliminary study of virus transmission, herd immunity and the potential impact of immunization. Epidemiol Infect. 1987;99:65-84.
  20. Okamoto M., Shitara T., Nakayama M., et al. Sudden deafness accompanied by asymptomatic mumps. Acta Otolaryngol. Suppl. 1994;514:45-8. doi: 10.3109/00016489409127557.
  21. Defendi G.L., Demirci C.S. Mumps Workup. Medscape. Updated: Jan 17, 2019.
  22. Bitnun S., Rakover Y, Rosen G. Acute bilateral total deafness complicating mumps. J Laryngol Otol. 1986;100:943-45. Doi: 10.1017/ s0022215100100362.
  23. Hashimoto H., Fujioka M., Kinumaki H. Kinki Ambulatory Pediatrics Study Group. An office-based prospective study of deafness in mumps. Pediatr Infect Dis J. 2009;28:173-75. doi: 10.1097/ INF0b013e31818a8ca8.
  24. Koskiniemi M., Vaheri A. Effect of measles, mumps, rubella vaccination on pattern of encephalitis in children. Lancet. 1989;i:31-4. Doi: 10.1016/ s0140-6736(89)91683-8.
  25. Russell R.R., Donald J.C. The neurological complications of mumps. Br Med J 1958;ii:27-30. doi: 10.1136/bmj.2.5087.27.
  26. Modlin J.F., Orenstein W.A., Brandling-Bennett A.D. Current status of mumps in the United States. J. Infect. Dis. 1975;132:106-9. Doi:10.1093/ infdis/132.1.106.
  27. Chaudary S., Jaski B.E. Fulminant mumps myocarditis. Ann Intern Med. 1989;110:569-70. doi: 10.7326/0003-4819-110-7-569.
  28. Gordon S.C., Lauter C.B. Mumps arthritis: a review of the literature. Rev Infect Dis. 1984;6:338-44. doi: 10.1093/clinids/6.3.338.
  29. Weisse M.E. The fourth disease, 1900-2000. Lancet. 2001;357(9252):299-301. Doi: 10.1016/ S0140-6736(00)03623-0.
  30. Cherry J.D., Lugo D. Measles virus. In: Cherry J.D., Harrison G.J., Kaplan S.L., Steinbach W.J., Hotez P.J., editors. Feigin and Cherry's textbook of pediatric infectious diseases. 8th ed. Philadelphia: Elsevier; 2019. P 1754-70.
  31. WHO, Weekly epidemiological record. 2016;91:525-36.
  32. Tanaka M., Harada T. Koplik spots in measles. Postgrad Med J. 2019;95(1126):454. doi: 10.1136/postgradmedj-2019-136739.
  33. Wang C.H. Image gallery: measles revival: Koplik's spots. Br J Dermatol. 2019;182(1):е4-е4. doi: 10.1111/bjd.18417.
  34. Teng S.S., Chua C.R., Chan Y.H., Ong G.Y. Identifying children with measles for isolation in a high-volume pediatric emergency department in Singapore. Pediatr Infect Dis J. 2019;38(12):1204-207. doi: 10.1097/INF0000000000002481.
  35. Perry R.T, Halsey N.A. The Clinical Significance of Measles: A Review. J Infect Dis. 2004;189(Suppl 1):S4-16. doi: 10.1086/377712.
  36. Wolfson L.J., et al. Estimates of measles case fatality ratios: a comprehensive review of community-based studies. Int J Epidemiol. 2009;38:192-205. doi: 10.1093/ije/dyn224.
  37. Plotkin S.A., Orenstein W.A., Offit P.A., Edwards K.M. (eds.). Vaccines (7th Edition) Chapter 21 - Measles vaccine. Elsevier, 2017. 1720 p.
  38. Palumbo P., et al. Population-based study of measles and measles immunization in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 1992;11(12):1008-14. doi: 10.1097/00006454-199211120-00004.
  39. Mina M.J., Kula T., Leng Y, et al. Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens, Science. 2019;366(6465):599-606. Doi: 10.1126/ science.aay6485.
  40. Rota P.A., Moss W.J., Takeda M., et al. Measles. Nat Rev Dis. 2016;2:16049. Doi: 10.1038/ nrdp.2016.49.
  41. Pirquet C., Das Verhalten der kutanen Tuberkulinreaktion wahred der Maern, Dtsch. Med. Wochenschr. 1908;34(30):1297-300. doi: 10.1055/s-0028-1135624.
  42. Griffin D.E. Measles virus-induced suppression of immune responses. Immunol Rev. 2010; 236:176-89. Doi: 10.1111fj.1600-065X.2010. 00925.x.
  43. Mina M.J., Metcalf C.J.E., de Swart R.L., et al. Grenfell Long-term measles-induced immunomodulation increasesoverallchildhoodinfectiousdiseasemortality Science. 2015;348:694-99. doi: 10.1126/science. aaa3662.
  44. de Vries R.D., de Swart R.L. Measles Immune Suppression: F. unctional Impairment or Numbers Game. PLoS Pathog. 2014;10(12):e1004482. doi: 10.1371/journal.ppat.1004482.
  45. Webster W.S. Teratogen update: Congenital rubella. Teratology 1998;58(1):13-23. Doi: 10.1002/ (SICI)1096-9926(199807)58:1<13::AID-TERA5>3.0.CO;2-2.
  46. Frey T.K. Molecular biology of rubella virus. Adv Virus Res. 1994;44:69-160. doi: 10.1016/s0065-3527(08)60328-0.
  47. WHO. Rubella virus nomenclature update: 2013. Wkly Epidemiol Rec. 2013;88:337-43.
  48. Abernathy E.S., et al. Status of global virologic surveillance for rubella viruses. J Infect Dis. 2011;204(Suppl. 1):524-32. Doi: 10.1093/ infdis/jir099.
  49. Zhu Z, et al. Rubella virus genotypes in the People's Republic of China between 1979 and 2007: a shif in endemic viruses during the 2001 Rubella Epidemic. J Clin Microbiol. 2010;48:1775-81. Doi: 10.1128/ JCM.02055-09.
  50. Zhu Z, et al. Evolutionary analysis of rubella viruses in mainland China during 2010-2012: endemic circulation of genotype 1E and introductions of genotype 2B. Sci Rep. 2015;5:7999. doi: 10.1038/ srep07999.
  51. Miller E, Waight P.A., Gay N., et al. The epidemiology of rubella in England and Wales before and after the 1994 measles and rubella vaccination campaign: Fourth joint report from the PHLS and the National Congenital Rubella Surveillance Program. Commun Dis Rep. 1997;7:R26-32.
  52. Hawker J., Begg N., Reintjes R., et al. Communicable Disease Control and Health Protection Handbook, 4th ed.; Wiley Blackwell: Oxford, UK, 2019. Р 205-7.
  53. Alford C.A., Neva F.A., Weller T.H. Virologic and Serologic Studies on Human Products of Conception after Maternal Rubella. N Engl J Med. 1964;271:1275-81. Doi: 10.1056/ NEJM196412172712501.
  54. Cutts F.T, Vynnycky E. Modelling the incidence of congenital rubella syndrome in developing countries. Int J Epidemiol. 1999;28:1176-84. Doi: 10.1093/ ije/28.6.1176.
  55. Banatvala J.E., Brown D.W.G. Rubella. Lancet. 2004;363:1127-37. doi: 10.1016/S0140-6736(04)15897-2.
  56. Atreya C.D, Mohan K.V., KulKarni B. Rubella virus and birth defects: Molecular insights into the viral teratogenesis at the cellular level. Birth Defects Res. A Clin Mol. Teratol. 2004;70:431-37. Doi: 10.1002/ bdra.20045.
  57. Toizumi M, Vo H.M., Dang D.A., et al. Clinical manifestations of congenital rubella syndrome: A review of our experience in Vietnam. Vaccine. 2019;37:202-9. Doi: 10.1016/j. vaccine.2018.11.046.
  58. Berger B.E., Navar-Boggan A.M., Omer S.B. Congenital rubella syndrome and autism spectrum disorder prevented by rubella vaccination-United States, 2001-2010. BMC. Public Health. 2011;11:340. doi: 10.1186/1471-2458-11-340.
  59. Ginsberg-Fellner F., Witt M.E., Yagihashi S., et al. Congenital rubella syndrome as a model for type 1 (insulin-dependent) diabetes mellitus: increased prevalence of islet cell surface antibodies. Diabetol. 1984;27(Suppl.):87-9. Doi: 10.1007/ BF00275655.
  60. Weil M.L., Itabashi H., Cremer N.E., et al. Chronic progressive panencephalitis due to rubella virus simulating subacute sclerosing panencephalitis. N Engl J Med. 1975;292(19):994-98. Doi: 10.1056/ NEJM197505082921903.
  61. Suzuki J., Goto H., Komase K., et al. Rubella virus as a possible etiological agent of Fuchs heterochromic iridocyclitis. Graefes Arch Clin Exp Ophthalmol. 2010;248(10):1487-91. doi: 10.1007/s00417-010-1434-6.
  62. Cimino L., Aldigeri R., Parmeggiani M., et al. Searching for viral antibodies and genome in intraocular fluids of patients with Fuchs uveitis and non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol. 2013;251(6):1607-12. doi: 10.1007/s00417-013-2287-6.
  63. Prechtl H.F The organization of behavioral states and their dysfunction. Semin Perinatol. 1992;16(4):258-63.
  64. Winchester S.A., Varga Z., Parmar D., Brown K.E. Persistent intraocular rubella infection in a patient with Fuchs' uveitis and congenital rubella syndrome. J Clin Microbiol. 2013;51(5):1622-24. doi: 10.1128/JCM.03239-12.
  65. Приказ Министерства здравоохранения РФ от 21 марта 2014 г. № 125н «Об утверждении национального календаря профилактических прививок и календаря профилактических прививок по эпи -демическим показаниям». @@Order of the Ministry of Health of the Russian Federation of March 21, 2014 No. 125n «On the approval of the national calendar of preventive vaccinations and the calendar of preventive vaccinations for epidemic indications». (In Russ.).
  66. Di Pietrantonj C., Rivetti A., Marchione P., et al. Vaccines for measles, mumps, rubella, and varicella in children. Cochrane Database Syst Rev. 2020;4:CD004407. doi: 10.1002/14651858. CD004407.pub4.
  67. Методические рекомендации по выявлению, расследованию и профилактике побочных проявлений после иммунизации, М., 2019. [Guidelines for the identification, investigation and prevention of adverse events after immunization, M., 2019. (In Russ.)].
  68. Demicheli V., Rivetti A., Debalini M.G., et al. Vaccines for measles, mumps and rubella in children. Evid Based Child Health 2013;8:2076-238. doi: 10.1542/peds.2007-1578.
  69. France E.K., Glanz J., Xu S., et al. Risk of immune thrombocytopenic purpura after measles-mumpsrubella immunization in children. Pediatrics. 2008;121:e687-92.
  70. Fantinato F.F.S.T., Vargas A., Carvalho S.M.D., et al. Anaphylaxis related to measles, mumps, and rubella vaccine in Santa Catarina State, Brazil, 2014 and 2015 Cadernos de Saude Publica. 2018;34(3):e00043617. doi: 10.1590/0102-311X00043617.
  71. Hooker B.S., Geier D., Kern J., et al. Measles-mumpsrubella vaccination timing and autism among young African American Boys: A reanalysis of CDC data. Transl Neurodegener. 2014;3:16. doi: 10.1186/2047-9158-3-16.
  72. Madsen K.M., Hviid A., Vestergaard M., et al. Population-based study of measles, mumps, and rubella vaccination and autism. N Engl J Med. 2002;347:1477-82. Doi: 10.1056/ NEJMoa021134.
  73. Davis R.L., Kramarz F.I, Bohlke K., et al. Measles-mumpsrubella and other measles-containing vaccines do not increase the risk for inflammatory bowel disease: A case-control study from the vaccine safety datalinkproject. Arch Pediatr Adolesc Med. 2001;155:354-59. doi: 10.1001/archpedi. 155.3.354.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО «Бионика Медиа», 2021

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах